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De novo TBR1 mutations in sporadic
autism disrupt protein functions
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Next-generation sequencing recently revealed that recurrent disruptive mutations in a few
genes may account for 1% of sporadic autism cases. Coupling these novel genetic data to
empirical assays of protein function can illuminate crucial molecular networks. Here we
demonstrate the power of the approach, performing the ﬁrst functional analyses of TBR1
variants identiﬁed in sporadic autism. De novo truncating and missense mutations disrupt
multiple aspects of TBR1 function, including subcellular localization, interactions with co-
regulators and transcriptional repression. Missense mutations inherited from unaffected
parents did not disturb function in our assays. We show that TBR1 homodimerizes, that it
interacts with FOXP2, a transcription factor implicated in speech/language disorders, and
that this interaction is disrupted by pathogenic mutations affecting either protein. These
ﬁndings support the hypothesis that de novo mutations in sporadic autism have severe
functional consequences. Moreover, they uncover neurogenetic mechanisms that bridge
different neurodevelopmental disorders involving language deﬁcits.
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A
utism spectrum disorders (ASD) are estimated to
affect 1 in 88 individuals and are characterized by a
classic triad of symptoms, which include impairments in
social interactions, deﬁcits in communication and a tendency
for repetitive stereotyped behaviours (CDC 2012). Inherited
genetic variants may account for 40% of the risk for developing
ASD1, but as is typical for complex traits, the effect of
individual common variants is small2. In recent years, next-
generation sequencing in ASD probands and their families has
revealed that rare and private genetic variants play a major
role in the aetiology of the disorder. These studies suggest that
loss-of-function mutations within any of a large number of
different genes may be sufﬁcient to cause ASD. For some genes,
such as AMT, PEX7 and SYNE1, the pathogenic mechanism
involves complete gene knockout through rare inherited
mutations, in a homozygous or compound heterozygous
state. For other genes, it is proposed that de novo loss-of-
function mutations disturbing one gene copy are responsible
for sporadic severe cases of ASD3–8.
Six genes—CHD8, DYRK1A, GRIN2B, PTEN, TBR1 and
TBL1XR1—have been observed to harbour de novo mutations
in multiple unrelated probands, strongly suggesting that hetero-
zygous disruption of any one of these genes is sufﬁcient to cause
ASD. It is estimated that mutations at these loci may account for
1% of sporadic cases8. TBR1 is of particular interest, because it
encodes a neuron-speciﬁc transcription factor of the T-box
family. T-box proteins have diverse biological roles9 and
haploinsufﬁciency of this class of regulatory protein has already
been established as a cause of human disease10—for instance,
ulnar-mammary syndrome and Holt–Oram syndrome are caused
by haploinsufﬁciency of TBX3 and TBX5, respectively11–13. TBR1
has established roles in patterning of the central nervous system,
including regulation of neuronal identities during cortical
development14. It is striking that among the small number of
known TBR1 targets, three—RELN, GRIN2B and AUTS2—have
been implicated in ASD3,7,8,15–18. Of particular interest, GRIN2B
is one of the six genes mutated recurrently in ASD. TBR1, RELN,
GRIN2B and AUTS2 may therefore form part of a molecular
network important for cortical development that is recurrently
mutated in ASD.
Moreover, there are data to suggest that the TBR1 protein may
be a potential interaction partner of the forkhead transcription
factor FOXP2 (ref. 19), another key regulator of central nervous
system development and function20. In the mammalian cortex,
TBR1 and FOXP2 show striking similarities in expression
pattern21–24, raising the possibility that they cooperate to
regulate gene networks in deep layer cortical neurons, and
other neural sites of co-expression. Mutations in FOXP2 cause a
rare disorder characterized by problems with sequencing speech,
and impairments in expressive and receptive language affecting
spoken and written domains20. Given that communication
deﬁcits are a core feature of ASD, it is plausible that TBR1 and
FOXP2 belong to a shared molecular network, which goes awry in
different neurodevelopmental disorders involving impaired
speech and/or language skills.
The recurrence of de novo TBR1 mutations in sporadic ASD
suggests that the identiﬁed mutations are likely to be pathogenic.
Nonetheless, functional experiments in model systems are
essential to determine the precise effect of mutations on protein
function and provide insight into the molecular mechanisms of
the disorder25. Follow-up of ﬁndings from genetic studies of
ASD is beginning to uncover the relevant gene networks
and biological pathways8,23,26–28. For example, two recent
independent reports highlight network clusters of ASD risk
genes that are important in mid-fetal brain development and
glutamatergic neuronal function23,28.
In the present study, we perform the ﬁrst functional
characterization of de novo TBR1 mutations identiﬁed in sporadic
cases of ASD, assessing their impact on multiple aspects of
protein function including protein expression, subcellular loca-
lization, transcriptional repression and protein–protein interac-
tions. We compare the functional consequences of these de novo
mutations with rare inherited TBR1 mutations of uncertain
clinical signiﬁcance, also found in probands with sporadic ASD.
Moreover, we deﬁne functional interactions between TBR1 and
FOXP2 proteins, assessing the impact of aetiological mutations in
each protein on these interactions. This work demonstrates how
functional analyses of de novo mutations from next-generation
sequencing can be used to deﬁne and expand a key molecular
network involved in neurodevelopmental disorders.
Results
TBR1 mutations in sporadic ASD. Four de novo TBR1 coding
mutations have been reported in sporadic ASD cases (Fig. 1a and
Table 1 and Supplementary Table 1)3,8. No homozygous or
compound heterozygous mutations in TBR1 were observed,
consistent with murine knockout models, which show neonatal
lethality22. However, there were several instances of heterozygous
rare variants inherited from an unaffected parent. Such mutations
could represent risk factors for ASD (for example, in combination
with other mutations in the genomic background)29.
Among the de novo mutations, the K228E and N374H
mutations involve amino-acid substitutions at highly conserved
positions within the T-box domain, which is involved in DNA-
binding and protein–protein interactions (Fig. 1b,c). These
mutations may therefore disturb these functions. The
A136PfsX80 and S351X mutations are predicted to yield
truncated proteins missing all or part of the T-box, which are
unlikely to retain DNA-binding capacity. For the A136PfsX80
variant, the additional 80 amino acids following the frameshift do
not show signiﬁcant homology to known protein domains, but do
alter the pI of TBR1 (pI of wild-type (WT) protein¼ 6.9, pI of
A136PfsX80¼ 8.9). All four mutations are suspected to be causal
due to their de novo occurrence coupled with in silico predictions
of functional signiﬁcance. In this study, we undertook empirical
assessment of the impact of these mutations on protein function.
Of the missense TBR1 mutations that were inherited from an
unaffected parent, we selected three—Q178E, Q418R and
P542R—for functional characterization based on the phenotype
of affected probands and/or predicted deleterious effects on
protein function (Fig. 1a and Table 1 and Supplementary
Table 1). A fourth mutation, V356M, was also chosen that was
previously identiﬁed through a targeted TBR1 screen in a family
with an ASD-affected sib-pair30 and is found within the T-box
(Fig. 1b,c).
De novo TBR1 mutations disrupt protein cellular localization.
The expression levels of WT and mutant TBR1 proteins were
assessed by western blotting of lysates from transfected cells
(Fig. 2a,b and Supplementary Fig. 1). WT TBR1 was detected at
B78 kDa. Protein variants arising from de novo and inherited
missense mutations were of identical molecular weight and
expressed in similar amounts to the WT protein, with the
exception of K228E, which showed increased expression. The
A136PfsX80 variant yielded a severely truncated product of only
B27 kDa and was expressed in higher levels compared with WT
TBR1. In contrast, the S351X variant showed reduced expression
and yielded a truncated protein of B43 kDa.
Subcellular localization of TBR1 protein variants was examined
in transfected HEK293 cells by immunocytochemistry (Fig. 2c).
Consistent with its role as a transcription factor, WT TBR1
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localized to the nucleus and was excluded from nucleoli.
Strikingly, all the de novo protein variants exhibited aberrant
subcellular localization, consistent with loss-of-function. The
A136PfsX80 variant exhibited a diffuse distribution in the
cytoplasm and occasionally also in the nucleus. The S351X
variant showed diffuse cytoplasmic distribution as well as large
aggregates throughout the cell. The K228E and N374H variants
retained import into the nucleus but a fraction formed abnormal
aggregates. In contrast to the de novo mutants, all the
variants arising from inherited mutations exhibited similar
localization to the WT protein. Similar results were obtained
when examining the subcellular localization of TBR1 variant
proteins in transfected human neuroblastoma SHSY5Y cells
(Supplementary Fig. 2).
Truncating TBR1mutations abolish transcriptional repression.
TBR1 can function as both an activator and repressor of
transcription31,32. TBR1-mediated repression of Fezf2 in layer 6
corticothalamic projection neurons restricts the origin of the
corticospinal tract to layer 5, and murine Tbr1 is able to repress
transcription in luciferase reporter assays through direct binding
to a conserved consensus element found near Fezf2 (ref. 32). We
demonstrated that human TBR1, which is 99.3% identical to the
mouse protein and has an identical T-box (Fig. 1b), was also able
to repress transcription from a luciferase reporter plasmid
containing this element (a decrease of 56±2%; Po0.001) (Fig. 3).
Both truncated TBR1 variants arising from de novo mutations
demonstrated signiﬁcant loss of repressive ability (Po0.001 and
Po0.01 respectively; Fig. 3), consistent with the total or partial
loss of the T-box in these variants. Moreover, the A136PfsX80
variant resulted in increased reporter expression compared with
cells transfected with an empty expression vector (Po0.001). This
observation may be due to aberrant protein–protein interactions
involving the new section of polypeptide resulting from the
T-box domain in TBR1
Human LWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVQ
Mouse LWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVQ
Zebra finch RRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVQ
Xenopus LWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVQ
Zebrafish LWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVT
Human GNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDTSQ
Mouse GNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDTSQ
Zebra finch GNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDTNQ
Xenopus GNRVYMHPDSPNTGAHWMRQEISFGKMKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDTSQ
Zebrafish GNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGATNNTGQMVVLQSLHKYQPRLHVVQVNEDGTEDTSQ
Human PGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
Mouse PGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
Zebra finch PGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
Xenopus PGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
Zebrafish PGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
T-box domain
TBR1 LWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWR--FQGGKWVPCGKADTN
T LWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWK--YVNGEWVPGGKPEPQ
TBX1 LWDEFNQLGTEMIVTKAGRRMFPTFQVKLFGMDPMADYMLLMDFVPVDDKRYRYAFHSSSWLVAGKADPA
TBX3 LWDQFHKRGTEMVITKSGRRMFPPFKVRCSGLDKKAKYILLMDIIAADDCRYK--FHNSRWMVAGKADPE
TBX6 LWKEFSSVGTEMIITKAGRRMFPACRVSVTGLDPEARYLFLLDVIPVDGARYR--WQGRRWEPSGKAEPR
TBR1 VQGNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDT
T APSC-VYIHPDSPNFGAHWMKAPVSFSKVKLTNK---LNGGGQ-IMLNSLHKYEPRIHIVRVG-------
TBX1 TPG-RVHYHPDSPAKGAQWMKQIVSFDKLKLTNN--LLDDNGH-IILNSMHRYQPRFHVVYVDPRKDSEK
TBX3 MPK-RMYIHPDSPATGEQWMSKVVTFHKLKLTNN--ISDKHGF-TILNSMHKYQPRFHIVRAN---DILK
TBX6 LPD-RVYIHPDSPATGAHWMRQPVSFHRVKLTNS--TLDPHGH-LILHSMHKYQPRIHLVRAA---QLCS
TBR1 SQPGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRD
T GPQRMITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLD
TBX1 YAEENFKTFVFEETRFTAVTAYQNHRITQLKIASNPFAKGFRD
TBX3 LPYSTFRTYLFPETEFIAVTAYQNDKITQLKIDNNPFAKGFRD
TBX6 QHWGGMASFRFPETTFISVTAYQNPQITQLKIAANPFAKGFRE
De novo:
Rare inherited:
T-box
p.A136PfsX80 p.K228E p.S351X p.N374H
p.Q178E p.V356M p.Q418R p.P542R
Figure 1 | TBR1 variants found in sporadic cases of ASD. (a) Schematic representation of TBR1 indicating changes found in sporadic ASD cases.
(b) Sequence alignment of the T-box domains of TBR1 in human (UniProt accession Q16650), mouse (Q64336), zebra ﬁnch (deduced from genome
sequence), xenopus (Q0IHV5) and zebraﬁsh (B5DE34). (c) Sequence alignment of the T-box domains of human TBR1 (Q16650), T protein (O15178),
TBX1 (O43435), TBX3 (O15119), TBX6 (O95947). Conserved residues are highlighted in green. Red arrows indicate residues mutated in sporadic
ASD cases. The blue arrow indicates the ﬁrst residue absent in the truncated S351X variant.
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frameshift mutation, especially given the high expression level of
the protein. In contrast to the truncated variants, the K228E and
N374H variants did not differ signiﬁcantly from WT TBR1 in
their ability to repress transcription, suggesting that they at least
partially retain DNA-binding capacity despite amino-acid
changes within the T-box. In our functional analyses of the
inherited missense mutations (of which only the V356M variant
represents an amino-acid change within the T-box), no variant
showed a signiﬁcant difference in repressive ability compared
with the WT protein (Fig. 3). Thus, according to this assay, such
mutations do not affect DNA-binding or transcriptional repres-
sion capabilities.
Truncating mutations disrupt TBR1–CASK interaction.
Interaction partners of TBR1 remain largely unknown—the only
protein reported to interact directly with TBR1 in the developing
cerebral cortex is CASK, a membrane-associated guanylate kinase
with roles in neural development and synaptic function31.
Heterozygous mutations disrupting CASK have been reported
in patients with severe intellectual disability (ID) and ASD4,33.
Interaction between the T-box and carboxy terminal region of
TBR1 and the guanylate kinase domain of CASK triggers
redistribution of CASK from the plasma membrane to the
nucleus, where it cooperates in the regulation of TBR1 target
genes31,34. Accordingly, in our experiments, co-expression of
CASK with WT TBR1 in HEK293 cells resulted in translocation
of CASK to the nucleus and extensive co-localization of TBR1
with CASK (Fig. 4a). In contrast, co-expression of CASK with the
truncated TBR1 variants resulting from de novo mutations
revealed a lack of CASK redistribution and loss of TBR1/CASK
co-localization (Fig. 4b). These ﬁndings are consistent with the
mapping of the CASK-binding site within the C-terminal region
of TBR1 (ref. 31). Intriguingly, CASK co-localizes in nuclear
aggregates with the K228E and N374H TBR1 variants, suggesting
that these mutants continue to interact with CASK and could
thereby trigger aberrant localization of CASK within neurons
(Fig. 4c). The amino-acid changes in TBR1 resulting from
inherited missense mutations do not disrupt recruitment of
CASK into the nucleus (Supplementary Fig. 3). The effects of the
TBR1 variant proteins on CASK localization were validated in
transfected SHSY5Y cells (Supplementary Fig. 4). Although three
of the mutations (V356M, Q418R, P542R) lie within the known
CASK-binding region, our ﬁndings suggest that these amino acids
are not crucial for CASK–TBR1 interaction.
TBR1 forms homodimers. Homodimerization has been observed
in a subset of T-box transcription factors, and in some cases is
required for binding to palindromic DNA sites35. To determine
whether TBR1 can form homodimers, we used the
bioluminescence resonance energy transfer (BRET) assay, a
method for monitoring protein–protein interactions in live
cells36. In this assay, a protein of interest is expressed as a
fusion protein with Renilla luciferase (donor), and its putative
interaction partner as a fusion protein with YFP (acceptor).
An interaction between the two proteins may bring the luciferase
and YFP moieties sufﬁciently close for non-radiative energy
transfer to occur, causing a measurable shift in the wavelength of
the emitted light (the BRET signal). When YFP–TBR1 and
luciferase–TBR1 fusion proteins were co-expressed in cells, a
signiﬁcant increase in BRET signal was observed compared with
when YFP–TBR1 was expressed with a control (nuclear-targeted)
luciferase, suggesting that TBR1 is able to homodimerize (Fig. 5a).
We conﬁrmed that the fusion proteins were correctly localized in
the cell (Supplementary Fig. 5).
All de novo and inherited variants carrying single amino-acid
changes retained the ability to dimerize with themselves and with
WT TBR1 in the BRET assay (Fig. 5a and Supplementary Fig. 6a).
Strikingly, co-expression of WT TBR1 and variants resulting from
de novo missense mutations (K228E, N374H) resulted in
extensive co-localization of WT and mutant proteins in nuclear
aggregates (see Supplementary Fig. 6b). Given that the mutations
occur in the heterozygous state in ASD cases, it is possible that
these TBR1 variants exert a dominant-negative effect by
interfering with functions of WT TBR1. In contrast, the truncated
proteins resulting from de novo mutations showed a complete
loss of interaction with WT TBR1 and a lack of self-association
Table 1 | Description of TBR1 mutations found in ASD.
Proband Type Variant
positionHg19
coordinates
dbSNP Reference
allele
Variant
allele
ESP
alleles
Cases Controls Mutation HGVS PolyPhen2
11480.p1 De novo Chr2:162273322 NA * C *¼ 13,006 1 0 Fs p.A136P
fsX80
N/A
13796.p1 De novo Chr2:162275481 NA * þC *¼ 13,006 1 0 Fs p.S351X N/A
13814.p1 De novo Chr2:162273603 NA A G A¼ 13,006
G¼0
1 0 Ms p.K228E Probably
damaging
09C86232A De novo Chr2:162275553 NA A C A¼ 13,006
C¼0
0-other
study3
0 Ms p.N374H Probably
damaging
12994.p1 Inherited (father) Chr2:162273453 NA C G C¼ 13,006
G¼0
2 1 Ms p.Q178E Possibly
damaging
14332.p1 Inherited (father)
— Inherited
(mother)
Chr2:162275499 rs147026901 G A G¼ 13,004
A¼ 2
0-other
study30
1 Ms p.V356M Probably
damaging
13702.p1 Inherited
(mother)
Chr2:162279942 NA A G A¼ 13,006
G¼0
1 0 Ms p.Q418R Benign
13060.p1 Inherited (father) Chr2:162280314 NA C G C¼ 13,006
G¼0
1 0 Ms p.P542R Probably
damaging
ASD, autism spectrum disorder; ESP, Exome Sequencing Project; Fs, frameshift; HGVS, Human Genome Variant Society nomenclature; Ms, missense.
For indels, the position listed in the human genome hg19 assembly follows the SAMtools/VCF convention of listing the position before the event; ‘*’ indicates a copy of the reference allele, while the ‘þ /
 ’ indicates the sequence inserted or deleted. Samples in our cohort included 2,446 cases and 762 controls. ESP data are taken from 6,503 non-ASD exomes from various ESP cohorts and denote
observed allele counts for the listed alleles. In our cohort, the p.V356M variant was identiﬁed in a control; it has also been reported in an ASD-affected sib pair by targeted sequencing of TBR1 in another
study30. The p.N374H variant was identiﬁed by exome sequencing in one ASD case in another study3.
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Figure 2 | Functional characterization of TBR1 protein variants identiﬁed in ASD. (a) Immunoblotting of whole-cell lysates from HEK293 cells co-
transfected with TBR1 variants in pcDNA4.HisMax and an empty pYFP plasmid as a control for testing transfection efﬁciency. The expected molecular
weights for the TBR1 proteins are: B78 kDa¼WT TBR1, K228E, N374H; B27 kDa¼A136PfsX80; B43 kDa¼ S351X. (b) Relative expression of TBR1
variant proteins as determined by densitometric analysis of western blot data (average of two independent experiments±s.e.m.). (c) Immunoﬂuorescence
staining of HEK293 cells transfected with TBR1 variants. Xpress-tagged TBR1 proteins are shown in green. Nuclei were stained with Hoechst 33342 (blue).
Scale bars¼ 10mm. Concordant results were seen in SHSY5Y cells, as shown in Supplementary Fig. 2.
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Figure 3 | De novo TBR1 truncating mutations abolish transcriptional repression activity. Luciferase reporter assays for transcriptional regulatory activity
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(Fig. 5a and Supplementary Fig. 6a). Loss of interaction with WT
protein may be due to the aberrant subcellular localization of the
truncated proteins; however, the absence of self-association
suggests that the T-box and/or C-terminal region of TBR1 may
be important for homodimerization.
To test this hypothesis, we created two truncated TBR1
proteins, N394X and S568X, which lack portions of the
C-terminal region but retain the complete T-box (Fig. 5b).
Expression of YFP-fusion proteins containing these two variants
was examined by western blotting and ﬂuorescence microscopy
Xpress YFP
CASKNo TBR1
CASKWT TBR1
Merge
CASKA136PfsX80
CASKS351X
K228E CASK
CASKN374H
Figure 4 | De novo truncating TBR1 mutations disrupt interactions with CASK. Fluorescence micrographs of HEK293 cells co-transfected with CASK and
(a) WT TBR1, (b) de novo truncating variants and (c) de novo missense variants. Xpress-tagged TBR1 proteins are shown in red (left-hand side), whereas
CASK fused to YFP is shown in green (middle). Nuclei were stained with Hoechst 33342 (blue). Scale bars for a–c¼ 10mm. Concordant results were seen
in SHSY5Y cells, as shown in Supplementary Fig. 4.
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(Fig. 5c,d and Supplementary Fig. 2b), which revealed that both
variants are predominantly nuclear but are also occasionally found
in cytoplasmic aggregates. The BRET assay showed that the S568X
variant, which lacks the ﬁnal 114 residues, can interact with itself
and with full-length TBR1 to a similar degree as the WT protein,
whereas the N394X variant, which lacks the ﬁnal 288 residues
following the T-box, shows a reduced ability to associate with itself
and with full-length TBR1 (Fig. 5e and Supplementary Fig. 6c),
indicating that the 394–568 region is important for homodimer-
ization. Homodimerization of the N394X synthetic variant was still
greater than the S351X variant found in ASD, suggesting that the
T-box is sufﬁcient for some homodimerization to occur, consistent
with previous studies37. Further experiments will be required to
pinpoint the region(s) within the C terminus of TBR1 that are
involved in dimerization, and to determine if the C-terminal region
is capable of self-association in absence of the T-box.
TBR1 interacts with the FOXP2 transcription factor. A prior
yeast two-hybrid screen suggested TBR1 as a putative interactor
of the FOXP2 transcription factor19. Rare disruptions of FOXP2
are implicated in a speech/language disorder, involving
developmental verbal dyspraxia accompanied by impairments
in expressive and receptive language20,38,39. Thus, an interaction
between TBR1 and FOXP2 could represent a molecular link
between distinct neurodevelopmental disorders involving
language deﬁcits. We used the BRET assay to analyse the
interaction of TBR1 with three naturally occurring FOXP2
isoforms found in the brain38,40 (Fig. 6a). The canonical FOXP2
isoform (isoform I) was able to interact with TBR1, as was
isoform III, which lacks the ﬁrst 92 amino acids (Fig. 6b). Isoform
10þ , which lacks the C-terminal region of FOXP2 spanning the
DNA-binding domain, showed a complete loss of interaction with
TBR1 (Fig. 6b). While FOXP2 isoforms I and III are nuclear,
isoform 10þ is localized to the cytoplasm, which may account
for its lack of interaction with WT TBR1 (Fig. 6c and
Supplementary Fig. 7). Alternatively, the C-terminal region of
FOXP2 may be involved in the interaction.
To locate the TBR1-binding site within FOXP2, we created a
series of four C-terminal deletions in FOXP2 (Fig. 6a). A nuclear-
targeting signal was appended to the C terminus of these
truncated proteins, which lack endogenous nuclear-targeting
signals. All these truncated proteins retained the ability to
interact with TBR1 in the BRET assay (Fig. 6d), indicating that
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the TBR1-binding site lies within the N-terminal 258 residues of
FOXP2. In the yeast two-hybrid screen which suggested TBR1
interaction, a region of FOXP2 encompassing residues 122–382
was used as the bait protein19. Together, these ﬁndings suggest
that the TBR1-binding site lies within region 122–258 of the
canonical FOXP2 isoform. This region includes two
polyglutamine (polyQ) tracts that are not present in other
FOXP family members. We generated FOXP2 variants that
lacked one or both polyQ tracts (Fig. 6a). All three variants
retained the ability to interact with TBR1 (Fig. 6d), indicating that
the polyQ tracts are not required for this interaction. We also
tested the interaction between TBR1 and two neurally expressed
FOXP2 paralogs, FOXP1 and FOXP4, which have Q-rich
domains but lack polyQ tracts (Supplementary Fig. 8). In the
BRET assay, both FOXP1 and FOXP4 were able to interact with
TBR1, conﬁrming our observations with the synthetic FOXP2
polyQ-deletion constructs. We conclude that TBR1 binding is
likely to involve the regions ﬂanking or between the two
polyglutamine tracts that are conserved in FOXP1 and FOXP4.
In agreement with these results, TBR1–FOXP2 interaction was
not disrupted by an in-frame deletion of E400 in FOXP2
(Supplementary Fig. 8), a residue which is known to be important
for FOXP2 homodimerization41.
An intact T-box is required for TBR1–FOXP2 interaction.
Next, we investigated the effects of de novo and inherited TBR1
mutations on interaction with FOXP2 (Fig. 6e). All four de novo
mutations abolished interactions with FOXP2. In contrast, three
TBR1 variants arising from inherited missense mutations
(Q178E, V356M and P542R) showed BRET signals comparable
with those seen with WT TBR1. Interestingly, the inherited
Q418R variant demonstrated reduced interaction with FOXP2.
This observation cannot be attributed to differential expression or
aberrant subcellular localization of the mutant protein. The
synthetic truncated TBR1 variants, both of which retain an intact
T-box, were still able to interact with FOXP2 (Fig. 6f). Together,
these data suggest that the T-box domain is mediating the
TBR1–FOXP2 interaction.
Aetiological FOXP2 mutations disrupt interaction with TBR1.
Finally, we investigated if the TBR1–FOXP2 interaction was
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affected by two different pathogenic FOXP2 point mutations,
each known to cause a rare monogenic speech and language
disorder (Fig. 7a). The R553H mutation yields a substitution
at a key residue in the DNA-binding domain of FOXP2, and was
identiﬁed as the result of linkage mapping in a large multi-
generational pedigree, the KE family38,42. The R328X mutation
introduces a premature stop codon to yield a protein product
lacking the leucine zipper dimerization domain and the DNA-
binding domain, and was discovered through targeted FOXP2
screening43. Both mutations severely disrupt protein function44.
Strikingly, both R553H and R328X mutations interfere with the
ability of FOXP2 to interact with TBR1 (Fig. 7b). For the R328X
variant, this loss of interaction with TBR1 may be largely due to
cytoplasmic mislocalization of FOXP2 ref. 44 (Fig. 7c and
Supplementary Fig. 7), since a comparable fragment of the
protein did interact with TBR1 when artiﬁcially directed to
the nucleus (Fig. 6d). The reduced interaction observed with
the R553H variant may also relate to its partial mislocalization
to the cytoplasm or protein aggregation44 (Fig. 7c and
Supplementary Fig. 7).
Discussion
We report the ﬁrst functional characterization of TBR1 mutations
identiﬁed in individuals with sporadic ASD (Table 2). We found
that the de novo mutations studied here disrupted one or more of
the aspects of protein function tested, whereas TBR1 mutations
inherited from unaffected parents had little or no impact on
protein function. These ﬁndings provide empirical support for the
effectiveness of focusing on de novo mutation events for
understanding the biology underlying sporadic cases of severe
neurodevelopmental disorders. Moreover, we showed that TBR1
interacts with FOXP2, a regulatory factor implicated in speech/
language disorder, demonstrating that this interaction is dis-
rupted by pathogenic mutations in either protein, suggesting a
molecular link between distinct neurodevelopmental disorders.
Two of the de novo mutations studied here are single-
nucleotide indels that introduce premature termination codons
into the coding sequence. These mutations occur before the ﬁnal
exon boundary and may trigger nonsense-mediated decay.
However, the degradation of mutated TBR1 transcripts in patient
cells cannot be assessed due to the absence of TBR1 expression in
peripheral tissues. The analyses of protein function described here
indicate that any truncated protein that is produced is non-
functional, since the protein exhibits loss of nuclear localization,
loss of interaction with the co-activator CASK and deﬁciency in
transcriptional repression activity. Coupled with the observation
that the truncated proteins cannot dimerize with WT TBR1, it
seems likely that the pathogenic mechanism of these mutations is
haploinsufﬁciency. This hypothesis is supported by the discovery
of heterozygous de novo microdeletions encompassing TBR1 in
probands with developmental delay, ASD and ID45–47.
Furthermore, anatomical and behavioural characterization of
heterozygous Tbr1 mice revealed that loss of one Tbr1 allele
impairs amygdalar axonal projections and results in cognitive
abnormalities48.
Two of the four de novo TBR1 mutations are missense
mutations within the T-box. The amino-acid residues affected by
the K228E and N374H mutations are conserved in T-box
sequences from divergent proteins (Fig. 1b,c), indicating
that they are likely to be important for the functioning of this
domain. These mutations showed more moderate effects
on protein function than those resulting in truncated TBR1
protein. They did not abolish nuclear import or transcriptional
repression activity in our assays, but were found to aggregate in
the nucleus. It is possible that subtle effects conferred by these
variants, not evident from in vitro experiments, may be important
in vivo. Interestingly, it was recently shown that the over-
expression of N374H in cultured amygdalar neurons from
heterozygous Tbr1 mice fails to rescue the axon outgrowth defect
observed in these neurons, whereas overexpression of WT TBR1
restored normal axonogenesis48. In our experiments, K228E and
N374H were no longer able to interact with either the co-
activator CASK or transcription factor FOXP2 (see below)
suggesting that regulation of different TBR1 target genes may
be selectively affected by these mutations, with particular
Merge
R328X
FOXP2
R553H
mCherryYFP
0
0.05
0.1
0.15
BR
ET
 ra
tio
Control FOXP2 R553H R328X
Acceptor: TBR1
Donor
FOXP2 TBR1
TBR1R553H
TBR1R328X
QL
QS
FOXZnF
LeuZ
R553H
Figure 7 | FOXP2 variants found in speech/language disorders do not interact with TBR1. (a) Schematic representation of FOXP2 variants found
in speech/language disorders. (b) BRET assays for interaction of WT TBR1 with FOXP2 variants. (c) Fluorescence images of HEK293 cells co-transfected
with TBR1 and FOXP2 variants. FOXP2 variants fused to YFP are shown in green (left-hand side), whereas TBR1 fused to mCherry is shown in red
(middle). Nuclei were stained with Hoechst 33342 (blue). Scale bar, 10mm. Concordant results were seen in SHSY5Y cells, as shown in Supplementary
Fig. 7. In b, bars represent the corrected mean BRETratios±s.e.m. of one experiment performed in triplicate. BRETassays were performed in HEK293 cells.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5954 ARTICLE
NATURE COMMUNICATIONS | 5:4954 |DOI: 10.1038/ncomms5954 | www.nature.com/naturecommunications 9
& 2014 Macmillan Publishers Limited. All rights reserved.
dysregulation of genes that are regulated by the TBR1–CASK
complex, and/or co-regulated by FOXP2. It is tempting
to speculate that CASK and/or FOXP2 might be involved in
TBR1-mediated axonogenesis.
Crystal structures of the T-box domains from human TBX3
and Xenopus laevis Xbra show that the residue equivalent to K228
makes direct contact with the DNA backbone in Xbra, but not in
TBX3, while the residues equivalent to N374 do not make direct
contact with DNA in either structure35,49. Thus, the missense
mutations observed in ASD probands may not completely abolish
DNA-binding activity, consistent with the retention of
transcriptional repression activity presented here, but could
have milder effects on the afﬁnity or speciﬁcity of DNA
recognition, or on protein stability. A crystal structure of TBR1
bound to DNA would help clarify the role of these residues in
DNA recognition. The K228E and N374H variants retained the
ability to dimerize with WT TBR1, causing the WT protein to
become localized to nuclear aggregates. Thus, the pathogenic
mechanism of these mutations may include a dominant-negative
effect that reduces the effective dosage of WT protein.
Overall, our data suggest that mutations that lead to a
reduction in the amount of functional TBR1 protein are causative
in sporadic cases of ASD. It is intriguing that there were variable
effects among these different causative mutations—aetiological
missense mutations within the DNA-binding domain did not
have as dramatic an effect on TBR1 protein function as the
truncating mutations in our assays. These ﬁndings are in line with
the expected odds ratio for these particular classes of mutation.
Interestingly, the severity of cognitive deﬁcits in individuals
carrying TBR1 mutations may reﬂect the severity of the
disruption to protein function. The ASD cases carrying truncating
mutations have mild-to-moderate ID, whereas those with
missense mutations have milder cognitive impairments
(Supplementary Table 1: non-verbal IQ scores: 41¼A136PfsX80;
63¼ S351X; 78¼K228E; 74¼N374H).
Our functional characterization of TBR1 mutations supports
the hypothesis that de novo mutations with highly deleterious
effects on protein function are an important cause of severe
sporadic ASD. With the exception of Q418R (see below), none of
the inherited variants displayed signiﬁcant effects on protein
function in our assays. While it remains possible that subtle
effects on protein function went undetected in these analyses,
overall our data do not support a contributory role for inherited
TBR1 mutations in sporadic ASD.
In addition to characterizing TBR1 mutants found in ASD, we
also investigated the interaction of TBR1 with the language-
related transcription factor FOXP2. We conﬁrmed an interaction
between these proteins and demonstrated that this interaction
involves the T-box of TBR1. Previous studies also highlighted the
role of the T-box in protein–protein interactions, such as between
TBR1 and CASK31 and between TBX5 and NKX2.5 (ref. 50). The
TBR1-binding site within FOXP2 was mapped to the regions
ﬂanking the two polyQ tracts, a part of the protein with no
established function. The interaction between TBR1 and FOXP2
is likely to be physiologically relevant due to temporal and spatial
overlap in expression of the two genes in several brain areas,
including layer 6 glutamatergic corticothalamic projection
neurons21–23,51,52. It will be interesting in future to identify the
speciﬁc developmental stages and neuronal subtypes in which
TBR1–FOXP2 interactions occur.
Individuals with mutations in either TBR1 or FOXP2 exhibit
speech and language deﬁcits, with the ASD probands showing
language delay and regression. Therefore, it is interesting that the
TBR1–FOXP2 interaction is disrupted both by de novo TBR1
mutations in ASD probands and by FOXP2 mutations found in
patients with a primary speech and language disorder (in the
absence of autism). Loss of TBR1–FOXP2 interaction may
therefore contribute to speech and language deﬁcits in the
context of two distinct neurodevelopmental disorders. Intrigu-
ingly, the interaction was also disrupted by the Q418R inherited
mutation, which is predicted to be benign (Table 1). The lack of
interaction between this mutant and FOXP2 may contribute to
the discrepancy between non-verbal IQ (86) and verbal IQ (58)
scores in this proband (Supplementary Table 1).
The importance of the TBR1–FOXP2 interaction to normal
speech and language development may lie in the co-regulation of
gene expression by these two transcription factors. The ASD-
susceptibility gene AUTS2 is a good candidate for co-regulation
by TBR1 and FOXP2. AUTS2 is a known TBR1 target53 and in
expression proﬁling of human cells with inducible FOXP2
expression, upregulation of AUTS2 was one of the most
signiﬁcant changes associated with induction of FOXP2
expression (P.D. and S.E.F., unpublished data).
In summary, our ﬁndings highlight the power of coupling
novel genetic ﬁndings with empirical data to ﬂesh out more
comprehensive molecular networks. By performing functional
characterization of de novo and rare inherited TBR1
mutations found in sporadic ASD, we identiﬁed novel protein
Table 2 | Summary of functional investigations of TBR1 variants found in ASD.
Protein–protein interactions
Expression levels Cellular localization Transcriptional
repression
CASK TBR1 FOXP2
WT TBR1 — Nuclear Yes Yes Yes Yes
De novo
A136PfsX80 4 WT Cytoplasmic, nuclear No No No No
S351X o WT Cytoplasmic, nuclear No No No No
K228E 4 WT Nuclear aggregates Yes Co-localization in nuclear aggregates Yes No
N374H Similar to WT Nuclear aggregates Yes Co-localization in nuclear aggregates Yes No
Rare inherited
Q178E Similar to WT Nuclear Yes Yes Yes Yes
V356M Similar to WT Nuclear Yes Yes Yes Yes
Q418R Similar to WT Nuclear Yes Yes Yes No
P542R Similar to WT Nuclear Yes Yes Yes Yes
ASD, autism spectrum disorder; WT, wild type.
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characteristics, such as TBR1 homodimerization, and built on
existing protein–protein networks with new interactions, at the
same time providing mechanistic bridges between neurodevelop-
mental disorders (Fig. 8). Next-generation screens of larger ASD
cohorts are set to reveal additional de novo mutations in
candidates including TBR1, GRIN2B, RELN and AUTS2—genes
that are recurrently mutated and belong to shared molecular
networks. Without experimental validation, such data sets will
most likely remain biologically uninformative. The functional
assays established here can be used to systematically investigate
effects of novel mutations disrupting members of this pathway.
At present, the lack of high-throughput testing of multiple genetic
variants hinders the extrapolation of such assays to the clinic for
diagnostic purposes. Development of such multiplex methods is
underway25. Coupled with strong genetic predictors, such as de
novo variants, this will undoubtedly aid in robustly deﬁning the
molecular networks that go awry in ASD.
Methods
Identiﬁcation of TBR1 variants. De novo and rare inherited mutations were
previously identiﬁed through whole exome or targeted resequencing3,6,8.
Cell culture and transfection. HEK293 and SHSY5Y cell lines were obtained from
ECACC (catalogue numbers: 85120602 for HEK293 and 94030304 for SHSY5Y).
HEK293 cells were grown in Dulbecco’s modiﬁed Eagle’s medium and SHSY5Y
cells in DMEM-F12 (Invitrogen). Media were supplemented with 10% fetal
bovine serum (Invitrogen). Transfections were performed using GeneJuice
(Merck-Millipore).
DNA expression constructs and site-directed mutagenesis. pcDNA4.-
HisMax.TBR1, pcDNA4.HisMax.A136PfsX80 and pJET1.2.CASK were synthesized
by GenScript USA. S351X, K228E, N374H, Q178E, V356M, Q418R and P542R
TBR1 variants were generated using the pcDNA4.HisMax.TBR1 as template with
the QuikChange II Site-Directed Mutagenesis Kit (Agilent) (primer sequences are
listed in Supplementary Table 2). Synthetic TBR1 truncation variants were PCR
ampliﬁed (N394X: Fwd 50-GAATTCATGCAGCTGGAGCACTGCCTT-30 , Rev
50-TCTAGATTAATCCCGAAATCCTTTTGC-30; S568X: Fwd 50-GAATTCATGC
AGCTGGAGCACTGCCTT-30 , Rev 50- TCTAGATTAGTTGGGCCAGCAGG
GCAG-30) and cloned into pCR2.1-TOPO (Invitrogen). TBR1 cDNAs were
subcloned using EcoRI/XbaI restriction sites into a modiﬁed pmCherry-C1 vector
(Clontech), as well as pLuc and pYFP expression vectors36. CASK cDNA was
subcloned using EcoRI/KpnI restriction sites into the pYFP expression vector.
FOXP variants were PCR ampliﬁed, cloned into pCR2.1-TOPO and subcloned
using BamHI/XbaI restriction sites into pLuc and pYFP expression vectors (primer
sequences are listed in Supplementary Table 3). The FOXP2.delQ variants were
generated using a PCR-based strategy. The control plasmids pLuc-control and
pYFP-control express the Renilla luciferase and YFP proteins with a C-terminal
nuclear localization signal36. All constructs were veriﬁed by Sanger sequencing.
SDS–PAGE and western blotting. Cells were transfected with equimolar con-
centrations of TBR1 expression plasmids. Whole-cell lysates were extracted by
treatment with lysis buffer (100mM Tris pH 7.5, 150mM NaCl, 10mM EDTA,
0.2% Triton X-100, 1% PMSF, 1 protease inhibitor cocktail; all from Sigma) for
10min at 4 C, before centrifuging at 10,000 g for 30min at 4 C to remove cell
debris. Proteins were resolved on 4–15% Tris–Glycine gels and transferred onto
polyvinylidene ﬂuoride membranes. Membranes were probed with Invitrogen
mouse anti-Xpress (for pcDNA4.HisMax constructs; 1:1,000) or Clontech mouse
anti-EGFP (for pYFP constructs; 1:8,000) overnight at 4 C, followed by incubation
with HRP-conjugated goat anti-mouse IgG for 45min at room temperature
(Bio-Rad; 1:2,000). Proteins were visualized using Novex ECL Chemiluminescent
Substrate Reagent Kit (Invitrogen) and the ChemiDoc XRSþ System (Bio-Rad).
Equal protein loading was conﬁrmed by stripping blots and reprobing using Sigma
anti-b-actin antibody (1:10,000). Bands were quantiﬁed by densitometry using the
Chemidoc XRSþ System image analysis software (Bio-Rad). A value for the
transfection efﬁciency of TBR1 constructs was obtained by dividing the YFP signal
by the b-actin signal. The relative expression of TBR1 variants was then derived by
dividing the Xpress signal by the transfection efﬁciency.
Immunoﬂuorescence. Cells were seeded onto coverslips coated with poly-L-lysine
(Sigma) and 36 h post transfection, cells were ﬁxed using 4% paraformaldehyde
solution (Electron Microscopy Sciences) for 10min at room temperature. Cells
were stained with mouse anti-Xpress (1:500) followed by Alexa Fluor 488-con-
jugated goat anti-mouse IgG (Hþ L; 1:1,000) (both Invitrogen) to visualize pro-
teins expressed from pcDNA4.HisMax. YFP and mCherry fusion proteins were
visualized by direct ﬂuorescence. Nuclei were visualized with Hoechst 33342
(Invitrogen). Fluorescence images were obtained using a LSM510 confocal
microscope with LSM Image Software or an Axiovert A-1 ﬂuorescent microscope
with ZEN Image Software (Zeiss).
Luciferase assays. The pGL3-CMV ﬁreﬂy luciferase reporter plasmid including
the Tbr1-binding site near Fezf2 was a kind gift of Prof. Sestan, Yale University32.
Cells were transfected with 45 ng of ﬁreﬂy luciferase reporter construct, 5 ng of
Renilla luciferase normalization control (pRL-TK; Promega) and 200 ng TBR1
expression construct (WT or mutant in pcDNA4.HisMax) or empty vector
(pcDNA4.HisMax). Forty-eight hours post transfection, ﬁreﬂy luciferase and
Renilla luciferase activities were measured in a TECAN F200PRO microplate
reader using the Dual-Luciferase Reporter Assay system (Promega).
BRET assay. BRET assays were performed as described36. Brieﬂy, cells were
transfected with pairs of YFP and luciferase fusion proteins in 96-well plates.
EnduRen (60 mM; Promega) was added to cells 36–48 h after transfection. Four
hours later, emission readings (integrated over 10 s) were taken using a TECAN
F200PRO microplate reader using the Blue1 and Green1 ﬁlter sets. Expression
levels of the YFP-fusion proteins were monitored by taking ﬂuorescence readings
using the ﬁlter set and dichroic mirror suitable for green ﬂuorescent protein
(excitation 480 nm, emission 535 nm). The corrected BRET ratio was obtained as
follows: [Green1(experimental condition)/Blue1(experimental condition)] [Green1(control
condition)/Blue1(control condition)]. The control proteins were Renilla luciferase and
YFP fused to a C-terminal nuclear localization signal. The BRET assay setup,
including the design of appropriate controls and data interpretation, is extensively
discussed in Deriziotis et al.36
Statistical signiﬁcance. The statistical signiﬁcance of the luciferase reporter assays
was analysed using a one-way analysis of variance and a Tukey’s post hoc test.
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